Prescient Therapeutics (formerly Virax Holdings) is a clinical-stage company that develops drugs to treat cancers. It provides PTX-200, a drug candidate that inhibits AKT tumor survival pathway, which plays a key role in the development of breast and ovarian cancer as well as leukemia. Additionally, the company offers PTX-100, a drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1).